Butyrate and GLP-1: A hand holding an Ozzi watermelon stick pack over a glass of water on a wooden desk, with the Ozzi pouch behind

Butyrate and GLP-1: How Your Gut's Own Fatty Acid Supports GLP-1

TL;DR: Butyrate is a fatty acid your gut bacteria make from fiber. It stimulates the L-cells in your gut wall, the cells that release GLP-1, your body's own fullness hormone. The research is still early, and it's one of the most interesting ideas in gut health right now.

Why are researchers interested in butyrate and GLP-1?

Researchers are interested in butyrate and GLP-1 because the gut cells that release GLP-1 carry sensors that detect butyrate (Tolhurst 2012). Those cells, called L-cells, sit right where your gut bacteria make butyrate.

Butyrate is a short-chain fatty acid. Your gut bacteria make it when they ferment fiber you can't digest yourself. It's the main fuel for the cells lining your colon.

GLP-1 is a hormone your own gut releases after you eat. It tells your brain you're full, and it slows how fast your stomach empties. Our guide to GLP-1 covers the hormone in full.

What is the theory behind butyrate and GLP-1?

The theory is that butyrate lands on sensors on your gut's L-cells, and the L-cells answer by releasing GLP-1. It happens in four steps.

Step 1You eat fiberIt reaches your colon undigested.
Step 2Bacteria make butyrateYour gut bacteria ferment that fiber.
Step 3L-cells sense itSensors on these gut cells detect butyrate.
Step 4GLP-1 is releasedYour brain gets the signal that you are full.

The sensors have names: FFAR2 and FFAR3. They sit on the surface of your L-cells and respond to short-chain fatty acids like butyrate.

When a short-chain fatty acid lands on a sensor, calcium rises inside the L-cell. That calcium signal triggers the release of GLP-1 (Tolhurst 2012).

There may be a second route, through your nerves.

Our guide to the vagus nerve and appetite explains that route.

What have studies of butyrate and GLP-1 found so far?

So far, lab research shows butyrate stimulates L-cells to release GLP-1 (Tolhurst 2012, Yadav 2013), and in people one 45-day trial saw GLP-1 rise while two other trials saw no change.

A trial that measured GLP-1

In a human trial, 60 adults with type 2 diabetes took sodium butyrate, a prebiotic fiber, both, or a placebo for 45 days. GLP-1 rose in the two groups that took butyrate, compared with placebo (Roshanravan 2017).

A year of high-fiber eating

In another human trial, 28 adults ate either a high-fiber cereal or a low-fiber cereal every day for a year. In the high-fiber group, butyrate was higher after 9 months. After 12 months, their GLP-1 was about 25% higher than when they started (Freeland 2010).

A weight result that fits the theory

In a 2026 trial, 46 adults followed the same reduced-calorie diet for 12 weeks. Half took 1,875 mg of sodium butyrate a day, and half took a placebo.

Among the adults without diabetes, the butyrate group lost about 15 pounds (7.0 kg). The placebo group lost about 7 pounds (3.2 kg) (Testa 2026).

That trial did not measure GLP-1, so it can't tell us why. The adults with type 2 diabetes in the same trial saw no difference in weight.

How could the butyrate and GLP-1 research play out?

Larger human trials could confirm that more butyrate in the gut means a stronger GLP-1 signal after meals, or the effect in people could turn out smaller than the lab work suggests.

If it works

In the best case, larger human trials confirm the simple version of the story. More butyrate in the gut means a stronger GLP-1 signal after meals.

It would be a gentle effect, meal by meal. Your body clears its own GLP-1 from the blood within minutes (Müller 2019). It rises when you eat and fades soon after.

The first human signals point this way: the GLP-1 rise in the 45-day trial, and the slow climb in the year-long fiber trial.

If it falls short

Not every human trial has seen it. In a trial of 50 adults on a reduced-calorie diet, the group that took sodium butyrate for 8 weeks saw weight and waist size fall. Their GLP-1 did not change (Amiri 2025).

A smaller trial in 12 men tested single doses of a butyrate-rich fat. It also saw no change in GLP-1 (van Deuren 2022).

Location is a puzzle. L-cells are most crowded in the lower gut (Eissele 1992). A swallowed capsule is absorbed much higher up. In one human study, blood butyrate peaked about 20 minutes after butyrate capsules (La Monica 2025).

So a capsule's butyrate may not reach many L-cells directly. The nerve route could be how it works instead. Or fiber, which makes butyrate right where the L-cells live, may turn out to be the stronger lever.

Your body uses butyrate fast. Colon cells burn most of it for fuel, and the liver clears most of the rest. In a human study, only about 2% of the butyrate delivered to the colon reached the general bloodstream (Boets 2017).

GLP-1 may not be the only route. When short-chain fatty acids were delivered to the colon of 12 men, a second fullness hormone called PYY went up (Canfora 2017). Butyrate's effect on appetite may run through several signals at once.

How do you get more butyrate?

You can get more butyrate three ways: eat more fermentable fiber, add a prebiotic fiber, or take butyrate directly.

1. Eat more fermentable fiber. Your bacteria need raw material. Oats, beans, lentils, onions, garlic, asparagus and slightly green bananas all feed butyrate production. See how to increase butyrate naturally.

2. Add a prebiotic fiber. Prebiotic fibers are concentrated fuel for the bacteria that make butyrate. This is the slow-build route, and it adds up over months.

3. Take butyrate directly. A supplement supplies butyrate itself, with no waiting on your bacteria. The form matters, because plain butyrate smells rancid and some forms carry sodium or added oils.

Route How it adds butyrate Good to know
Fiber-rich foods Feeds the bacteria that make it Slow and steady; varies by person
Prebiotic fiber Concentrated fuel for those bacteria Can cause gas at first
Butyrate supplement Supplies butyrate directly Form matters: smell, sodium, oils

Our pick among the forms is L-lysine butyrate. It has a milder smell, no sodium and no added oils. The full comparison is in our guide to the best form of butyrate, and our butyrate research hub collects the rest.

We sell a butyrate supplement, which is why we read this research closely. Butyrate is in three Ozzi products: BIOMEnd Butyrate capsules (1,000 mg per serving), our Natural GLP-1 Supplement capsules and the Crave Crusher drink (500 mg each). The goal with all three is to support your own GLP-1.

Ozzi BIOMEnd Butyrate supplement bottle: 1,000 mg L-lysine butyrate per serving, 112 capsules

The form we chose

Ozzi BIOMEnd Butyrate

1,000 mg of BIOMEnd L-lysine butyrate per daily serving of 4 capsules. No sodium carrier and no added oils. 112 capsules, 28 servings per bottle. It is a dietary supplement.

See the butyrate supplement →

Frequently asked questions

Does butyrate increase GLP-1?
Butyrate stimulates the L-cells that release GLP-1, and lab research has shown that repeatedly. In people, a 45-day trial found a rise in GLP-1, and two other trials found no change. Larger human trials are the next step.

Can butyrate help with weight loss?
Butyrate is being studied for weight loss. In a 12-week trial of 46 adults on the same reduced-calorie diet, the adults without diabetes who took sodium butyrate lost more weight than those on placebo. It was a small trial, and butyrate is not a weight loss treatment.

About the author

Brandon is the founder of Ozzi. He reads the research himself and writes it up in plain English, with the sources listed so you can check them. More at Brandon's author page.

This article is for educational purposes and isn't medical advice. It describes published research on butyrate, not the effects of any Ozzi product. Ozzi products are dietary supplements and are not intended to diagnose, treat, cure, or prevent any disease. Talk to your healthcare provider before starting any supplement, especially if you have a medical condition or take medication.

References

  1. Tolhurst G, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012. PubMed 22190648
  2. Lin HV, et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS One. 2012. PubMed 22506074
  3. Yadav H, et al. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem. 2013. PubMed 23836895
  4. Li Z, et al. Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit. Gut. 2018. PubMed 29101261
  5. Roshanravan N, et al. Effect of butyrate and inulin supplementation on glycemic status, lipid profile and glucagon-like peptide 1 level in patients with type 2 diabetes: a randomized double-blind, placebo-controlled trial. Horm Metab Res. 2017. PubMed 28962046
  6. Freeland KR, et al. Adaptation of colonic fermentation and glucagon-like peptide-1 secretion with increased wheat fibre intake for 1 year in hyperinsulinaemic human subjects. Br J Nutr. 2010. PubMed 19664300
  7. Testa R, et al. Targeting weight loss and blood glucose control with oral sodium butyrate in overweight/obese adults with and without type 2 diabetes: a proof-of-concept randomized controlled trial. Clin Nutr. 2026. PubMed 41880673
  8. Amiri P, et al. Expression of PGC-1α, PPAR-α and UCP1 genes, metabolic and anthropometric factors in response to sodium butyrate supplementation in patients with obesity: a triple-blind, randomized placebo-controlled clinical trial. Eur J Clin Nutr. 2025. PubMed 39448815
  9. van Deuren T, et al. Butyrate and hexanoate-enriched triglycerides increase postprandrial systemic butyrate and hexanoate in men with overweight/obesity: a double-blind placebo-controlled randomized crossover trial. Front Nutr. 2022. PubMed 36687671
  10. Canfora EE, et al. Colonic infusions of short-chain fatty acid mixtures promote energy metabolism in overweight/obese men: a randomized crossover trial. Sci Rep. 2017. PubMed 28539646
  11. Eissele R, et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest. 1992. PubMed 1499644
  12. Boets E, et al. Systemic availability and metabolism of colonic-derived short-chain fatty acids in healthy subjects: a stable isotope study. J Physiol. 2017. PubMed 27510655
  13. Müller TD, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019. PubMed 31767182
  14. La Monica MB, et al. A pharmacokinetic comparison of three butyrate products. Journal of Exercise and Nutrition. 2025;8(1):4. Journal page
Back to blog